Samalizumab
B-Cell Chronic Lymphocytic Leukemia
Explore 67 assets in B-Cell Chronic Lymphocytic Leukemia →Floatz Rating
C33/100
Confidence
Indicative
Sponsor
Alexion Pharmaceuticals, Inc.
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
18Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00648739CT.gov Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · B-Cell Chronic Lymphocytic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Samalizumab (this asset) | Alexion Pharmaceuticals, Inc. | P1/2 | C · 33 |
| Fludarabine | Ohio State University Comprehensive Cancer Center | P4 | BBB |
| Humax-Cd20 | Emory University | P4 | BBB |
| Acalabrutinib | Zulfa Omer | P4 | BBB |
| Cyclophosphamide | Ohio State University Comprehensive Cancer Center | P4 | BB |
| Chlorambucil | Janssen Research & Development, LLC | P3 | BB |
| Rituximab | Zulfa Omer | P4 | BB |
| Lenalidomide | Vitebsk Regional Clinical Cancer Centre | P3 | BB |
| Obinutuzumab | Paolo Caimi, MD | P3 | BB |
+42 more in the B-Cell Chronic Lymphocytic Leukemia cohort
Other indications for Samalizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia | — | P1/2 | C · 33 |
| Plasma Cell Myeloma | — | P1/2 | D · 28 |
| Cancer | — | P1 | D · 26 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Samalizumab in B-Cell Chronic Lymphocytic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/samalizumab-b-cell-chronic-lymphocytic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →